Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	11/2/2000 3:38:14 PM
From: nigel bates	Read Replies (1) of 4974

Nov. 2 /PRNewswire/ -- Avigen, Inc. (Nasdaq: AVGN - news) today announced the public offering of 1,658,329 shares of its Common Stock at a public offering price of $37.50 per share pursuant to its shelf registration statement. All of the shares are being offered by Avigen. Avigen is engaged in the development of gene therapy products for the treatment of inherited diseases. Avigen is developing its proprietary adeno-associated virus vector technology, known as ``AAV vectors,'' to deliver DNA to patients that are suffering from genetic diseases. AAV vectors are a relatively new system for gene therapy. Avigen believes its AAV vectors can be used to deliver genes for the treatment of hemophilia, metabolic and lysosomal storage diseases, such as Gaucher disease, and neural disorders, such as Parkinson's disease...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next